ICAAC 2015: Gilead’s Stribild Demonstrates Improved Safety and Efficacy Among Women Who Switched from a Multi-Pill Antiretroviral Drug Regimen

Dr. Sally Hodder, Director of the West Virginia Clinical and Translational Science Institute, will share the results from WAVES, the First International Phase 3 HIV Study to Enroll Only Women.

Women are routinely underrepresented in HIV clinical trials although they account for half of the global HIV epidemic. Consequently, current HIV treatment guidelines are based on data obtained primarily from men and generalized to women. Tune in to hear Dr. Sally Hodder explain how WAVES provides clinical safety and efficacy data to assist women and their clinicians in the informed selection about antiretroviral regimens.